
NASDAQHealthcareBiotechnology
最新数据
US$0.2843
−US$0.0262 · -8.44%
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
前收盘价
US$0.2843
−US$0.0262 · -8.44%
盘中时间采用ET。市场数据可能有所延迟。
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
日内区间
当前US$0.2843
52周区间
当前US$0.2843
盘中时间采用ET。市场数据可能有所延迟。
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
日内区间
当前US$0.2843
52周区间
当前US$0.2843
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1115.9万 USD | 999.4万 USD | 3447.7万 USD | 1385.1万 USD | 959.8万 USD |
| 销货成本 | 364.5万 USD | 392.7万 USD | 352.5万 USD | 364.1万 USD | 98.4万 USD |
| 毛利 | 751.4万 USD | 606.7万 USD | 3095.2万 USD | 1021万 USD | 861.4万 USD |
| 研究与开发 | 1.09亿 USD | 1.3亿 USD | 1.12亿 USD | 8223万 USD | 5225.5万 USD |
| 销售、一般及管理费用 | 3791.4万 USD | 4645.7万 USD | 3846.1万 USD | 3802万 USD | 2333.8万 USD |
| 营业费用 | 1.44亿 USD | 1.73亿 USD | 1.47亿 USD | 1.17亿 USD | 7559.3万 USD |
| 利息收入 | 800万 USD | — | 1070万 USD | 460万 USD | 14.8万 USD |
| 利息支出 | — | — | — | — | 8000 USD |
| 折旧和摊销 | 364.5万 USD | 392.7万 USD | 352.5万 USD | 162.2万 USD | 98.4万 USD |
| 营业利润 | −1.36亿 USD | −1.67亿 USD | −1.16亿 USD | −1.06亿 USD | −6697.9万 USD |
| 净利润 | −1.48亿 USD | −1.49亿 USD | −1.02亿 USD | −9942.1万 USD | −6692.3万 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$1.00
上涨空间 251.74%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI100.51万0.00%6893亿 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM67.08万0.00%715.37亿 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF57.73万0.00%302亿 USD0.05%US$211.44-3.21%
iShares Russell 2000 Value ETFIWN25.01万—130.46亿 USD0.24%US$198.84-2.08%
Vanguard Russell 2000 ETFVTWO22.59万0.00%168亿 USD0.06%US$103.76-2.76%
iShares Biotechnology ETFIBB19.61万0.00%105.27亿 USD0.44%US$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA17.38万0.00%204.47亿 USD0.03%US$30.51-2.83%
Fidelity Enhanced Small Cap ETFFESM11.09万—67.4亿 USD0.28%US$41.85-2.49%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。